• Corpus ID: 43549358

Methotrexate binding to human plasma proteins.

  title={Methotrexate binding to human plasma proteins.},
  author={Lidia Skibińska and C. Ramlau and Jerzy Zaluski and Bogdan Olejniczak},
  journal={Polish journal of pharmacology and pharmacy},
  volume={42 2},
The percentage of methotrexate (MTX) binding to plasma protein was 50.4 +/- 1.9 in healthy subject, and 32.3 +/- 3.6 in patients with cancer (breast carcinoma in most cases). Drugs used in combination with MTX in therapy (vincristine, vinblastine, cyclophosphamide, 5-fluorouracil, prednisone) depress the MTX binding to albumins. MTX binds to two kinds of albumins binding sites, with different binding constants: K1 = 8.88 mM-1 and K2 = 1.76 mM-1. 

Morphine in Children with Cancer

Morphine binding was influenced by concentrations of albumin, AAG and morphine itself, but not by age, and was unaffected by pH in samples from patients.

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

The results support previous findings suggesting that PPI co-administration is associated with delayed elimination of plasma MTX in patients with HDMTX therapy and cannot be explained solely by the inhibitory effects of PPIs on BCRP-mediated MTX transport.

Prediction of methotrexate CNS distribution in different species - influence of disease conditions.

The effect of malignant effusions on methotrexate disposition

Malignant effusions were noticeable only in the disposition phase of MTX resulting in an apparent "third space" and the resulting increase in half-life may be associated with unanticipated toxicity.

Measurement of methotrexate in human cerebrospinal fluid using a chemiluminescence immunoassay intended for serum and plasma matrices

This study measured methotrexate (MTX) concentrations in the CSF using a high‐performance liquid chromatography (HPLC) method intended for analyzing CSF matrices and a chemiluminescence immunoassay (CLIA)method intended for assessing serum and plasma matrices.

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

The final model indicates that MTXCL was dependent on the change in the ratio between P1 and P3, DIS and creatinine clearance, and it is plausible that it reflects a function modified in response to the drug.

Prediction of brain target site concentrations on the basis of CSF PK: Impact of mechanisms of blood-to-brain transport and within brain distribution

The aim of the research was to develop a preclinical brain distribution model, allowing the prediction of human brain target site concentrations on the basis of preclinical data, and understanding of time-dependent (also non-steady state) kinetics of the unbound drug in brainECF and CSF is essential.

An Inexpensive, In-House-Made, Microdialysis Device for Measuring Drug-Protein Binding.

An inexpensive, in-house made microdialysis device is described that is suitable for measuring the binding of small molecules including drug candidates to serum proteins or other macromolecules. The

The Extension of the LeiCNS-PK3.0 Model in Combination with the “Handshake” Approach to Understand Brain Tumor Pathophysiology

The LeiCNS-tumor model demonstrated a potential to predict PK profiles of small molecule drugs in brain tumors, for which quantitative information on pathophysiological alterations is available, and contribute to the efficient and successful drug development for malignant brain tumors.

Protein Binding of Anticancer Drugs

The methodological aspects of protein-ligand interactions, the relationship between protein binding and drug disposition, and the clinical relevance of free drug monitoring in cancer patients are discussed.